Regeneron: When Good Isn’t Good Enough

Regeneron released solid trial data today, but it wasn’t enough to please investors. Its shares have dropped more than 5% today.
Source: Barrons

Leave a Reply

Your email address will not be published.

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>